Compared to the gusher of financings flooding into public companies, private companies have had to work hard to attract venture capital. But unlike previous years there may be signs that this situation is changing rapidly judging by the amount of venture capital (VC) that has been raised year-to-date. Read More
As we described in last week’s issue there is no doubt that agents that target the PD-1 pathway have generated much excitement among investors. There are several candidate drugs in late-stage development as anti-PD-1 immunotherapies targeting various solid cancers such as melanoma. In addition to the pharma players in this space, a number of biotech companies are focusing on this pathway. Many of their compounds are still at the early discovery and preclinical stages, but they are already showing potential. Read More
